Tourmaline Bio to Present at Upcoming Investor Conferences

Rhea-AI Summary

Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotech company, has announced its participation in two upcoming investor conferences. CEO Sandeep Kulkarni is scheduled to present at:

• H.C. Wainwright 26th Annual Global Investor Conference in New York on September 9, 2024 at 12:00 pm ET
• Cantor Global Healthcare Conference in New York on September 17, 2024 at 3:40 pm ET

Both presentations will be available via live webcast on the company's website under the 'Events and Presentations' section. Replays will be archived on the site after each event. Tourmaline Bio focuses on developing transformative medicines for immune and inflammatory diseases.

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is expected to participate in the following investor conferences:

H.C. Wainwright 26^th Annual Global Investor Conference, New York
Fireside Chat
Monday, September 9, 2024 at 12:00 pm ET

Cantor Global Healthcare Conference, New York
Fireside Chat
Tuesday, September 17, 2024 at 3:40 pm ET

A live webcast of both presentations will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalinebio.com. A replay of the webcasts will be archived on the Tourmaline Bio website following each event.

About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006).

About Pacibekitug
Pacibekitug (also referred to as TOUR006) is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. Pacibekitug has been previously studied in 448 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing pacibekitug in TED and ASCVD as its first two indications, with additional diseases under consideration.

Investor Contact
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com

Media Contact
Scient PR
Sarah Mishek
SMishek@ScientPR.com

FAQ

When is Tourmaline Bio (TRML) presenting at the H.C. Wainwright Global Investor Conference?

Tourmaline Bio (TRML) is presenting at the H.C. Wainwright 26th Annual Global Investor Conference on Monday, September 9, 2024 at 12:00 pm ET in New York.

What time is Tourmaline Bio's (TRML) presentation at the Cantor Global Healthcare Conference?

Tourmaline Bio (TRML) is scheduled to present at the Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 3:40 pm ET in New York.

How can investors access Tourmaline Bio's (TRML) investor conference presentations?

Investors can access live webcasts of Tourmaline Bio's (TRML) presentations under the 'Events and Presentations' section in the News & Investors area of the company's website at ir.tourmalinebio.com.

Will replays of Tourmaline Bio's (TRML) investor conference presentations be available?

Yes, replays of Tourmaline Bio's (TRML) investor conference presentations will be archived on the company's website following each event.